Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 6Phase 3 5Phase 1/2 3Phase NA 2Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Desmoplastic Small Round Cell Tumor 2Stomach Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Pelvic Neoplasms 1Neuroblastoma 1Neoplasms 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Liposarcoma 1Leukemia, Large Granular Lymphocytic 1Fallopian Tube Neoplasms 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 7fludarabine 4Dasatinib 2zimberelimab 1pembrolizumab 1palbociclib 1olaparib 1fluorodopa F 18 1Vincristine 1Vemurafenib 1Topotecan 1Temozolomide 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Magnetic Resonance Spectroscopy 1Influenza Vaccines 1Fluoxetine 1Fluorodeoxyglucose F18 1Everolimus 1Etoposide 1Doxorubicin 1Decitabine 1Cholestanetriol 26-Monooxygenase 1CVAD protocol 1Busulfan 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recurrence × Doxorubicin × Clear all
NCT01184885 2025-05-04

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
7 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡